The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • ☂️-@lemmy.ml
    2·
    2 days ago

    i can only imagine someone buying that data is up to no good. who is “regeneron” really?